{
    "clinical_study": {
        "@rank": "40154", 
        "arm_group": [
            {
                "arm_group_label": "Group 1: 12 to 17 years of age", 
                "arm_group_type": "Experimental", 
                "description": "100 mg Delamanid BID for 6 months"
            }, 
            {
                "arm_group_label": "Group 2: 6 to 11 years of age", 
                "arm_group_type": "Experimental", 
                "description": "50 mg Delamanid BID for 6 months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to assess the safety, tolerability, pharmacokinetics, and\n      efficacy of long-term (6-month) treatment with delamanid plus an optimized background\n      regimen of of other anti-tuberculosis drugs in pediatric patients who completed Trial\n      242-12-232."
        }, 
        "brief_title": "A 6-Month Safety, Efficacy, and Pharmacokinetic Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Multidrug Resistant Tuberculosis", 
            "Pediatric"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Tuberculosis", 
                "Tuberculosis, Multidrug-Resistant"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a phase 2, open-label, multiple-dose, multicenter trial to assess the safety,\n      tolerability, pharmacokinetics, and efficacy of delamanid plus an optimized background\n      regimen in pediatric patients with MDR-TB over a 6 month treatment period. This long-term\n      trial, an extension of Trial 242-12-232, will be conducted in patients who have completed\n      Trial 232. Trial 242-12-233  will initially be conducted sequentially in two groups of\n      pediatric patients by age group: Group 1 (ages 12 to 17 years) and Group 2 (ages 6 to 11\n      years).\n\n      Younger age groups (Group 3, [3 to 5 years] and Group 4, [0 to 2 years]) will be enrolled\n      when the pediatric formulation becomes available. Details describing Groups 3 and 4 will be\n      included in an amendment to the protocol."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Successfully completed Trial 242-12-232\n\n          -  Confirmed diagnosis of MDR-TB OR\n\n          -  Presumptive diagnosis of MDR TB including one of the following:\n\n               -  Persistent cough lasting > 2 weeks\n\n               -  Fever, weight loss, and failure to thrive\n\n               -  Chest radiograph consistent with TB\n\n               -  Sputum smear positive for acid-fast bacilli AND\n\n               -  Household contact of a person with known MDR TB or a person who died while\n                  appropriately taking drugs for sensitive TB/OR\n\n          -  On first-line TB treatment but with no clinical improvement\n\n          -  Negative urine pregnancy test for female patients who have reached menarche\n\n          -  Written informed consent/assent\n\n        Exclusion Criteria:\n\n          -  Positive test for HIV, previously identified as having HIV, or laboratory evidence of\n             active hepatitis B or C\n\n          -  History of allergy to metronidazole and any disease or condition in which\n             metronidazole is required\n\n          -  Use of amiodarone within 12 months or use of other predefined antiarrhythmic\n             medications within 30 days prior to first dose of delamanid\n\n          -  Serious concomitant conditions\n\n          -  Preexisting cardiac conditions\n\n          -  Abnormalities in Screening ECG (including AV block, BBB or hemi-block, QRS\n             prolongation > 120 msec, or QTcF > 450 msec in both males and females)\n\n          -  Concomitant condition such as renal impairment characterized by serum creatinine\n             levels >1.5 mg/dL, hepatic impairment (ALT or AST > 3 x ULN), or hyperbilirubinemia\n             characterized by total bilirubin > 2x ULN\n\n          -  Current diagnosis of severe malnutrition or kwashiorkor\n\n          -  Rifampicin and/or moxifloxacin within 1 week prior to the first dose of delamanid\n\n          -  Lansky Play Performance Score < 50 or Karnofsky Score < 50"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01859923", 
            "org_study_id": "242-12-233"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group 1: 12 to 17 years of age", 
                "Group 2: 6 to 11 years of age"
            ], 
            "intervention_name": "Delamanid", 
            "intervention_type": "Drug", 
            "other_name": "OPC-67683"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Tuberculosis", 
            "Tuberculosis, Multidrug-Resistant", 
            "Mycobacterium Infections", 
            "Actinomycetales Infections", 
            "Gram-Positive Infections", 
            "Bacterial Infections", 
            "Pediatric"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dasmari\u00f1as City", 
                        "country": "Philippines", 
                        "state": "Cavite"
                    }, 
                    "name": "De La Salle Health Sciences Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quezon City", 
                        "country": "Philippines", 
                        "state": "Metro Manila"
                    }, 
                    "name": "Lung Center of the Philippines"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ysterplaat", 
                        "country": "South Africa", 
                        "state": "Cape Town"
                    }, 
                    "name": "Brooklyn Chest Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Philippines", 
                "South Africa"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC-67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs Over a 6-Month Treatment Period", 
        "overall_contact": {
            "email": "corey.best@otsuka-us.com", 
            "last_name": "Corey Best, MBA", 
            "phone": "919-544-8143"
        }, 
        "overall_official": {
            "affiliation": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
            "last_name": "Jeffrey Hafkin, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of Subjects reporting an Adverse Event", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "description": "Summary Statistics of subjects with clinically significant abnormal laboratory test results, vitals, EGGs and Physical Examinations", 
                "measure": "Safety Summary", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Delamanid and plasma concentrations predose (0 hours) on Day 1", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "Delamanid and plasma concentrations predose (0 hours) on Day  56", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 56"
            }, 
            {
                "description": "Delamanid and plasma concentrations predose (0 hours) on Day 154", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 154"
            }, 
            {
                "description": "Delamanid and plasma concentrations predose (0 hours) on Day 182", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 182"
            }, 
            {
                "description": "Delamanid and plasma concentrations predose (0 hours) on Day  210 at the theoretical predose time when delamanid would have been administered", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 210"
            }, 
            {
                "description": "Delamanid and plasma concentrations predose (0 hours) at any time point on Day 14", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }, 
            {
                "description": "Delamanid and plasma concentrations predose (0 hours) at any time point on Day 98", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 98"
            }, 
            {
                "description": "Delamanid and plasma concentrations predose (0 hours) at any time point on Day 189", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 189"
            }, 
            {
                "description": "Delamanid and plasma concentrations predose (0 hours) at any time point on Day 196", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 196"
            }, 
            {
                "description": "Delamanid and plasma concentrations predose (0 hours) at any time point on Day 203", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 203"
            }, 
            {
                "description": "Delamanid and plasma concentrations predose (0 hours) at any time point on Day 238", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Day 238"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01859923"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "DM-6705 plasma concentrations and changes in QTc interval using the paired pharmacokinetic/pharmacodynamic assessments on Days 1, 56, 154, 182, and 210.", 
                "measure": "Pharmacokinetics/pharmacodynamics", 
                "safety_issue": "Yes", 
                "time_frame": "365 Days"
            }, 
            {
                "description": "Proportion of subjects with resolution of TB symptoms based on investigator evaluation.", 
                "measure": "Resolution of TB Symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "365 Days"
            }
        ], 
        "source": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Development & Commercialization, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}